On February 23, 2023 Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company"), a company developing new approaches for the treatment of cancer and fibrosis, reported that Amplia Head of Translational Biology, Dr Terrie-Anne Cock, will present a lecture at the 2nd Next Generation Kinase Inhibitors Summit currently underway in Boston, USA (Press release, Amplia Therapeutics, FEB 23, 2023, View Source;[email protected] [SID1234627657]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation, entitled ‘Targeting Focal Adhesion Kinase (FAK) for the treatment of cancer and fibrotic diseases’ describes preclinical and Phase 1 clinical data for Amplia’s lead FAK inhibitor AMP945. A copy of the presentation, to be given at Friday 6:30am AEDT, is attached to this announcement.

Amplia CEO, Dr Chris Burns, commented: "Being invited to present our research at such a highly respected, industry-focused conference devoted to kinase inhibitor drug development, reflects the importance of our research at Amplia and our standing in the kinase field, internationally. Further, it allows us to promote the quality of the work being conducted at Amplia to biotech and pharma companies around the world."

This ASX announcement was approved and authorised for release by the CEO of Amplia Therapeutics.